Inmed pharmaceuticals inc. announces results from a phase 2 clinical trial in epidermolysis bullosa

An exploratory clinical evaluation of the phase 2 clinical trial data showed a positive indication of enhanced anti-itch activity for inm-755 cannabinol ("cbn") cream versus the control cream alone. the results for non-wound itch were not statistically significant in favor of inm-755 cbn cream due, in part, to the clinically important anti-itch effect of the underlying control cream.
INM Ratings Summary
INM Quant Ranking